MaxCyte (NASDAQ:MXCT) Raised to “Hold” at Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Tuesday.

MXCT has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a research report on Monday, December 29th. Craig Hallum reduced their target price on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, March 25th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.50.

MaxCyte Stock Down 1.1%

MaxCyte stock opened at $0.68 on Tuesday. The firm has a market cap of $72.26 million, a P/E ratio of -1.57 and a beta of 1.22. The business has a fifty day moving average of $0.83 and a two-hundred day moving average of $1.31. MaxCyte has a twelve month low of $0.64 and a twelve month high of $2.96.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $6.76 million for the quarter, compared to the consensus estimate of $9.16 million. MaxCyte had a negative return on equity of 22.15% and a negative net margin of 135.14%. Equities analysts expect that MaxCyte will post -0.42 earnings per share for the current year.

Institutional Trading of MaxCyte

Institutional investors have recently made changes to their positions in the business. Prudential Financial Inc. purchased a new position in MaxCyte during the 2nd quarter worth $26,000. State of Wyoming acquired a new position in MaxCyte during the 2nd quarter valued at about $38,000. Kwmg LLC raised its stake in MaxCyte by 75.8% in the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after buying an additional 11,135 shares during the last quarter. BNP Paribas Financial Markets raised its stake in MaxCyte by 266.6% in the second quarter. BNP Paribas Financial Markets now owns 26,008 shares of the company’s stock valued at $57,000 after buying an additional 18,913 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in MaxCyte in the second quarter worth about $60,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.